Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine to Prevent Culture Confirmed Influenza Infection.

Trial Profile

Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine to Prevent Culture Confirmed Influenza Infection.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2015

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza B virus infections
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Most Recent Events

    • 16 Feb 2011 Results published in the Lancet, according to a Baxter Healthcare media release.
    • 12 Mar 2010 Results have been presented at the International Congress on Infectious Disease (ICID 2010), according to a Baxter International media release.
    • 29 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top